. Author manuscript; available in PMC: 2013 Mar 1.

Published in final edited form as: J Allergy Clin Immunol. 2012 Jan 10;129(3):687–693.e1. doi: 10.1016/j.jaci.2011.12.001

Table 1.

Patient characteristics^*

	SR asthma n=11	SS asthma n=8^**
Age, yrs, (Mean±SE)	33.1±4.7	31.5±5.2
Gender (Male/Female)	3/8	2/6
Race (C/AA/Other)	2/6/3	5/1/2
Baseline FEV₁% predicted, (Mean±SE)	67.0±3.3	65.8±2.2
FEV₁% reversal with Albuterol, (Mean±SE)	17.3±2.8^***	30.3±3.8
FEV₁% change after Prednisone burst, (Mean±SE)	0.8±2.0^****	17.5±2.4
Corticosteroid medications^***** ICS/LABA ICS none	6 3 2	4 0 4

In this study, blood was collected at Visit 1 and Visit 3 for the in vitro steroid response assays

^**

one SS patient gave blood only at Visit 1

^***

p<0.05;

^****

p<0.001 as compared to SS asthmatics

^*****

For the SR and SS asthmatics that received ICS/LABA or ICS the Mean±SD of the ICS dose in budesonide equivalents was 408±107 µg and 840±188 µg, respectively.